• Something wrong with this record ?

The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023)

D. Fischerova, F. Frühauf, A. Burgetova, IS. Haldorsen, E. Gatti, D. Cibula

. 2024 ; 16 (4) : . [pub] 20240214

Status not-indexed Language English Country Switzerland

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc24005790

Grant support
NU21-03-00461 and MH CZ-DRO-VFN64615 Ministry of Health of the Czech Republic

Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern imaging techniques. After five years (2023), an update of the ESGO-ESTRO-ESP recommendations was performed, further confirming this statement. Transvaginal/transrectal ultrasound (TRS/TVS) or pelvic magnetic resonance (MRI) enables tumor delineation and precise assessment of its local extent, including the evaluation of the depth of infiltration in the bladder- or rectal wall. Additionally, both techniques have very high specificity to confirm the presence of metastatic pelvic lymph nodes but fail to exclude them due to insufficient sensitivity to detect small-volume metastases, as in any other currently available imaging modality. In early-stage disease (T1a to T2a1, except T1b3) with negative lymph nodes on TVS/TRS or MRI, surgicopathological staging should be performed. In all other situations, contrast-enhanced computed tomography (CECT) or 18F-fluorodeoxyglucose positron emission tomography combined with CT (PET-CT) is recommended to assess extrapelvic spread. This paper aims to review the evidence supporting the implementation of diagnostic imaging with a focus on ultrasound at primary diagnostic workup of cervical cancer.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005790
003      
CZ-PrNML
005      
20240412131005.0
007      
ta
008      
240405s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers16040775 $2 doi
035    __
$a (PubMed)38398166
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fischerova, Daniela $u Gynecologic Oncology Centre, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic $1 https://orcid.org/0000000272243218 $7 xx0074804
245    14
$a The Role of Imaging in Cervical Cancer Staging: ESGO/ESTRO/ESP Guidelines (Update 2023) / $c D. Fischerova, F. Frühauf, A. Burgetova, IS. Haldorsen, E. Gatti, D. Cibula
520    9_
$a Following the European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) joint guidelines (2018) for the management of patients with cervical cancer, treatment decisions should be guided by modern imaging techniques. After five years (2023), an update of the ESGO-ESTRO-ESP recommendations was performed, further confirming this statement. Transvaginal/transrectal ultrasound (TRS/TVS) or pelvic magnetic resonance (MRI) enables tumor delineation and precise assessment of its local extent, including the evaluation of the depth of infiltration in the bladder- or rectal wall. Additionally, both techniques have very high specificity to confirm the presence of metastatic pelvic lymph nodes but fail to exclude them due to insufficient sensitivity to detect small-volume metastases, as in any other currently available imaging modality. In early-stage disease (T1a to T2a1, except T1b3) with negative lymph nodes on TVS/TRS or MRI, surgicopathological staging should be performed. In all other situations, contrast-enhanced computed tomography (CECT) or 18F-fluorodeoxyglucose positron emission tomography combined with CT (PET-CT) is recommended to assess extrapelvic spread. This paper aims to review the evidence supporting the implementation of diagnostic imaging with a focus on ultrasound at primary diagnostic workup of cervical cancer.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Frühauf, Filip $u Gynecologic Oncology Centre, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic $1 https://orcid.org/0000000241611890 $7 xx0207709
700    1_
$a Burgetova, Andrea $u Department of Radiology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic $1 https://orcid.org/0000000299752338 $7 xx0163957
700    1_
$a Haldorsen, Ingfrid S $u Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University Hospital, N-5021 Bergen, Norway $u Section for Radiology, Department of Clinical Medicine, University of Bergen, 5020 Bergen, Norway $1 https://orcid.org/0000000193137564
700    1_
$a Gatti, Elena $u Department of Biomedical Science for Health, University of Milan, 20133 Milan, Italy $1 https://orcid.org/0009000937746061
700    1_
$a Cibula, David $u Gynecologic Oncology Centre, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, 121 08 Prague, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 4 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38398166 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130958 $b ABA008
999    __
$a ok $b bmc $g 2076032 $s 1215552
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 16 $c 4 $e 20240214 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a NU21-03-00461 and MH CZ-DRO-VFN64615 $p Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20240405

Find record

Citation metrics

Archiving options